Cite
HARVARD Citation
Koch, S. et al. (n.d.). A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part. Journal for immunotherapy of cancer. p. . [Online].